Jamieson announces the completion of another management advisory transaction involving the $100m equity investment by Novo Growth Equity and Warburg Pincus into the pharmaceuticals business, Arcimedes Pharma.
Archimedes is a European specialty pharmaceutical company with an established commercial organisation in the UK, France, Germany, Ireland and Spain.
Jamieson was appointed by the management team on the structuring and negotiating of their equity and incentive arrangements with the introduction of new capital.
The funding round is the largest raised by a private European biopharma company in the last 15 years and is Novo Growth Equity’s first investment since it was established at the beginning of 2009. The funds will be used to establish Archimedes’ operations in the US and support the growth of the successful specialty pharma business in Europe. The funds will also be used to support the global commercial launch of PecFent.
